RT Journal Article
SR Electronic
T1 A nonrandomized phase 2 trial of EG-Mirotin, a novel, first-in-class, subcutaneously delivered peptide drug for non-proliferative diabetic retinopathy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.30.21267814
DO 10.1101/2021.12.30.21267814
A1 Yoo, Seunghoon
A1 You, Dae Hyuk
A1 Lee, Jeongyoon
A1 Hong, H. Christian
A1 Lee, Sung Jin
YR 2022
UL http://medrxiv.org/content/early/2022/04/07/2021.12.30.21267814.abstract
AB Aim EG-Mirotin (active ingredient EGT022) targets non-proliferative diabetic retinopathy (NPDR), the early stage of retinopathy. EG-Mirotin reverses capillary damage before NPDR progresses to an irreversible stage. EG-Mirotin safety and efficacy were investigated in patients with type 1 or type 2 diabetes mellitus and moderate-to-severe NPDR.Methods In this open-label, single-arm, single-center, exploratory phase II study, 10 patients (20 eyes) received EG-Mirotin once a day (3 mg/1.5 ml sterile saline) for 5 days and were evaluated for ischemic index changes and safety. End-of-study was approximately 8±1 weeks (57±7 days) after the first drug administration.Results EG-Mirotin injections were well tolerated with no dose-limiting adverse events, serious adverse events, or deaths. Four treatment-emergent adverse events (TEAEs) unrelated to the investigational drug were observed in 2 out of 10 participants (20.00%) who had received the investigational drug. The overall average percent change in ischemic index at each evaluation point compared to baseline was statistically significant (Greenhouse-Geisser F=9.456, p=0.004 for the main effect of time), and a larger change was observed when the baseline ischemic index value was high (Greenhouse-Geisser F=10.946, p=0.002 for time × group interaction).Conclusions EG-Mirotin was well tolerated and reversed diabetes-induced ischemia and leakage of capillaries in the retina.Competing Interest StatementDae Hyuk You, Jeongyoon Lee, and Sung Jin Lee are independently contracted consultants of EyeGene Inc. and H. Christian Hong is an employee of EyeGene Inc. Clinical TrialClinical Research Information System (CRIS): KCT0005124 The above KCT0005124 has been listed in International Clinical Trials Registry Platform by World Health Organization: https://trialsearch.who.int/Trial2.aspx?TrialID=KCT0005124Funding StatementThis study was funded by EyeGene Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Soonchunhyang University Hospital gave ethical approval for this work: SCHUH2020-03-004I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors